Cancer diagnostics company Genecast has launched of ADPS BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity. Currently available for research use only (RUO), the ADPS BRAF mutation test kit has 0.0001% detection sensitivity, which the company says is 100 times higher than other products available. Its EGFR and JAK2 mutation kits have detection sensitivity of 0.01%. The BRAF mutation test kit can diagnose four BRAF mutations found primarily in thyroid cancer and melanoma and since the ADPS technology is based on qPCR, it can reduce the expense and shorten clinical test time. Genecast plans to launch KRAS, NRAS, PIK3CA, pTERT, IDH1, and IDH2 mutation test kits (RUO) by the end of 2019, and complete certification of CE-IVD for 9 Oncology kits by the first half of 2020.